Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method

References

• MattickRPBreenCKimberJDavoliMBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database Syst Rev20142CD00220724500948
   PubMed Web of Science ®Google Scholar
• AnchersenKClausenTGossopMHansteenVWaalHPrevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment studyAddiction200910499399919392907
   PubMed Web of Science ®Google Scholar
• DegenhardtLRandallDHallWLawMButlerTBurnsLMortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives savedDrug Alcohol Depend200910591519608355
   PubMed Web of Science ®Google Scholar
• Swiss Society of Addiction Medicine (SSAM)Clinical Recommendations for Substitution-assisted Treatment in Opioid Dependence 2012 [Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit 2012]Mediscope AG, ZurichSwiss Society of Addiction Medicine2013 Available from: http://www.ssam.ch/SSAM/sites/default/files/EmpfehlungenSGB_2012_FINAL_05032013.pdfAccessed March 30, 2015
   Google Scholar
• JasinskiDRPrestonKLLaboratory studies of buprenorphine in opioid abusersCowanALewisJBuprenorphine: Combatting Drug Abuse with a Unique OpioidNew York, NYWiley-Liss, Inc1995189211
   Google Scholar
• FDA US Food and Drug AdministrationBuprenorphine – Drug LabelSilver Spring, MDFood and Drug Administration2010 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarket-DrugSafetyInformationforPatientsandProviders/UCM191529.pdfAccessed November 21, 2015
   Google Scholar
• Center for Substance Abuse TreatmentClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid AddictionRockville, MDSubstance Abuse and Mental Health Services Administration2004 Available from: http://www.buprenorphine.samhsa.gov/Bup_Guidelines.pdfAccessed November 30, 2015
   Google Scholar
• LevinFRFischmanMWConnerneyIFoltinRWA protocol to switch high-dose, methadone-maintained subjects to buprenorphineAm J Addict199761051169134072
   PubMed Web of Science ®Google Scholar
• MattickRPAliRWhiteJMO’BrienSWolkSDanzCBuprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patientsAddiction20039844145212653814
   PubMed Web of Science ®Google Scholar
• PaniPPMaremmaniIPirastuRTagliamonteAGessaGLBuprenorphine: a controlled clinical trial in the treatment of opioid dependenceDrug Alcohol Depend200060395010821988
   PubMed Web of Science ®Google Scholar
• PetitjeanSStohlerRDéglonJJDouble-blind randomized trial of buprenorphine and methadone in opiate dependenceDrug Alcohol Depend2001629710411173173
   PubMed Web of Science ®Google Scholar
• SchottenfeldRSPakesJROlivetoAZiedonisDKostenTRBuprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuseArch Gen Psychiatry1997547137209283506
   PubMed Web of Science ®Google Scholar
• ComerSDWalkerEACollinsEDBuprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteersPsychopharmacology (Berl)200518166467516025322
   PubMed Web of Science ®Google Scholar
• RothmanRNiQXuHBuprenorphine: a review of the binding literatureCowanALewisJBuprenorphine: Combatting Drug Abuse with a Unique OpioidNew York, NYWiley-Liss, Inc19951929
   Google Scholar
• BickelWKAmassLCreanJPBadgerGJBuprenorphine dosing every 1, 2, or 3 days in opioid-dependent patientsPsychopharmacology (Berl)199914611111810525745
   PubMed Web of Science ®Google Scholar
• WalshSLJuneHLSchuhKJPrestonKLBigelowGEStitzerMLEffects of buprenorphine and methadone in methadone-maintained subjectsPsychopharmacology (Berl)19951192682767675960
   PubMed Web of Science ®Google Scholar
• ResnickRBKestenbaumRSWashtonAPooleDNaloxone-precipitated withdrawal: a method for rapid induction onto naltrexoneClin Pharmacol Ther197721409413849672
   PubMed Web of Science ®Google Scholar
• LoimerNSchmidRWPresslichOLenzKContinuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatmentJ Psychiatr Res19892381862547057
   PubMed Web of Science ®Google Scholar
• MendelsonJJonesRTWelmSBrownJBatkiSLBuprenorphine and naloxone interactions in methadone maintenance patientsBiol Psychiatry199741109511019146820
   PubMed Web of Science ®Google Scholar
• HämmigREinleitung einer Substitutionsbehandlung mit Buprenorphin unter vorübergehender Überlappung mit Heroinkonsum: ein neuer Ansatz (“Berner Methode”). [Induction of a buprenorphine substitution treatment with temporary overlap of heroin use: a new approach (“Bernese Method”)]Suchttherapie201011129132 German
   Web of Science ®Google Scholar
• MeissnerWLeyendeckerPMueller-LissnerSA randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipationEur J Pain200913566418762438
   PubMed Web of Science ®Google Scholar
• GossopMThe development of a Short Opiate Withdrawal Scale (SOWS)Addict Behav1990154874902248123
   PubMed Web of Science ®Google Scholar
• VogelMDürsteler-MacFarlandKMWalterMProlonged use of benzodiazepines is associated with childhood trauma in opioid-maintained patientsDrug Alcohol Depend2011119939821715105
   PubMed Web of Science ®Google Scholar
• Lingford-HughesAWelchSPetersLNuttDBAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAPJ Psychopharmacol20122689995222628390
   PubMed Web of Science ®Google Scholar
• NordtCVogelMDürstelerKMStohlerRHerdenerMA comprehensive model of treatment participation in chronic disease allowed prediction of opioid substitution treatment participation in Zurich, 1992–2012J Clin Epidemiol2015681346135426073899
   PubMed Web of Science ®Google Scholar
• HessMBoeschLLeisingerRStohlerRTransdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptomsAm J Addict20112048048121838850
   PubMed Web of Science ®Google Scholar